281
Participants
Start Date
February 12, 2018
Primary Completion Date
April 26, 2024
Study Completion Date
November 30, 2025
BMS-986253
Specified dose on specified days
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0040, Lausanne
Local Institution - 0037, Brussels
Local Institution - 0088, Wollstonecraft
Local Institution - 0090, Melbourne
Local Institution - 0095, Melbourne
Local Institution - 0096, Adelaide
Local Institution - 0097, Perth
Local Institution - 0039, Zurich
Local Institution - 0082, Kortrijk
Local Institution - 0036, Ghent
Local Institution - 0041, Sankt Gallen
Local Institution - 0025, New York
Local Institution - 0002, New York
Local Institution - 0034, Berlin
Local Institution - 0067, Marseille
Local Institution - 0001, Pittsburgh
Local Institution - 0047, Santiago de Compostela
Local Institution - 0026, Rozzano-milano
Local Institution - 0042, Milan
Local Institution - 0053, Hamburg
Local Institution - 0012, Columbia
Local Institution - 0003, Lutherville
Local Institution - 0015, Fairfax
Local Institution - 0008, Norfolk
Local Institution - 0045, Madrid
Local Institution - 0022, Madrid
Local Institution - 0023, Madrid
Local Institution - 0044, Málaga
Local Institution - 0009, Greenville
Local Institution - 0101, Marietta
Local Institution - 0087, Atlanta
Local Institution - 0100, Atlanta
Local Institution - 0021, Pamplona
Local Institution - 0102, Toulouse
Local Institution - 0085, Nantes
Local Institution - 0043, Forlì
Local Institution - 0004, Ann Arbor
Local Institution - 0052, Mainz
Local Institution - 0076, Omaha
Local Institution - 0054, Tübingen
Local Institution - 0059, Springdale
Local Institution - 0028, Oklahoma City
Local Institution - 0068, Paris
Local Institution - 0010, Dallas
Local Institution - 0013, Tyler
Local Institution - 0018, Houston
Local Institution - 0006, San Antonio
Local Institution - 0011, Austin
Local Institution - 0027, Napoli
Local Institution - 0007, Lakewood
Local Institution - 0058, Salt Lake City
Comprehensive Cancer Centers Of Nevada, Las Vegas
Local Institution - 0099, Los Angeles
Local Institution - 0069, Villejuif
Local Institution - 0017, Eugene
Local Institution - 0060, Boston
Local Institution - 0005, Hackensack
Local Institution - 0032, New Brunswick
Local Institution - 0014, Fort Worth
Local Institution - 0091, Ballarat Central
Local Institution - 0030, Edmonton
Local Institution - 0029, Vancouver
Local Institution - 0078, Victoria
Local Institution - 0020, Toronto
Local Institution - 0055, Toronto
Local Institution - 0056, Montreal
Local Institution - 0071, Krakow
Local Institution - 0077, Warsaw
Local Institution - 0049, Lund
Local Institution - 0024, Manchester
Local Institution - 0083, Glasgow
Local Institution - 0019, Birmingham
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY